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Usefulness of 18F-FDG PET in Diagnosing
Cardiac Sarcoidosis
Osamu Manabe, Keiichiro Yoshinaga, Hiroshi Ohira,
and Noriko Oyama-Manabe
Abstract Sarcoidosis is a multisystem granulomatous disorder of unknown etio-
logy. The number of patients with cardiac involvement is considered to be limited,
but cardiac sarcoidosis is a very serious and unpredictable aspect of sarcoidosis
resulting in conduction-system abnormalities and heart failure. The severity of
cardiac involvement depends on the extent and location of the granulomatous
lesions.
When establishing a diagnosis, 18F-fluorodeoxyglucose (18F-FDG) positron
emission tomography (PET) is a useful tool to detect active inflammatory lesions
associated with sarcoidosis. The heart uses different energy sources including free
fatty acids (FFA), glucose, and others. The 18F-FDG is an analog of glucose, and for
the precise evaluation of the extent and severity of cardiac involvement, recent
studies have focused on reducing physiological myocardial 18F-FDG uptake. Long
fasting and dietary modification, such as observing a low-carbohydrate or high-fat
diet, are the recommended regimens for preparations to make a precise evaluation.
The FFA level before the PET scan could be a predictor of the success to the
suppression of the physiological 18F-FDG accumulation.
With 18F-FDG PET therapy monitoring or risk stratification based on quanti-
tative 18F-FDG accumulation becomes possible. The quantification of the volume
and intensity of 18F-FDG uptake could assist in predicting the clinical outcomes and
in evaluating the efficiency of steroid treatments.
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This report provides a summary of the usefulness of 18F-FDG PET in its
current status as a diagnostic modality for cardiac sarcoidosis.
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16.1 Background
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology. It is
characterized by noncaseating, epithelioid granulomas. Typically, young or middle-
aged adults are affected. In Japan, the annual incidence ranges from 1 to 2 cases per
100,000 of the population. The bilateral hilar and mediastinal lymph nodes, lungs,
skin, musculoskeletal system, and eyes are well known to be involved in lesions.
Essentially all organs, including the heart, may potentially be involved [1, 2].
Sarcoidosis patient treatment generally follows a favorable clinical course.
However, about 30 % of patients suffer chronically or experience recurrence.
Granulomas forming in an organ can affect how the organ functions and be a
cause of signs and symptoms. Especially, prognosis is related to the presence of
cardiac lesions [3].
The frequency of cardiac involvement varies and is significantly influenced by
ancetstry. In Japan over 25 % of cases with sarcoidosis experience symptomatic
cardiac involvement, whereas in the USA and Europe, only about 5 % of cases
present cardiac involvement. Autopsy studies in the USA have shown the frequency
of cardiac involvement to be about 20 %, whereas autopsy studies in Japan have
shown a frequency above 50 % [4–6].
16.2 Diagnostic Criteria for Cardiac Sarcoidosis
Histologic analysis of operative or endomyocardial biopsy specimens could be the
irrefutably best standard in diagnosing cardiac sarcoidosis. However, it is not
feasible to perform endomyocardial biopsies on all suspected regions, and myo-
cardial biopsies tend to have lower sensitivity in the diagnosis of cardiac sarcoid-
osis. Therefore, the Japanese Ministry of Health and Welfare (JMHW) guidelines
for diagnostic imaging have been used as the diagnostic standard since early times
[7]. The JMHW criteria include both the histologic and the clinical diagnosis
groups. For the clinical diagnosis group, the positive findings of electrocardio-
graphy, echocardiography, and 67Ga scintigraphy are the major criteria; minor
criteria include findings of electrocardiography, echocardiography, perfusion
images, and cardiac magnetic resonance images. Among the criteria, 18F-fluoro-
deoxyglucose (18F-FDG) positron emission tomography (PET) is not included in
the 2006 criteria; it is only noted as a comment that abnormal 18F-FDG accumu-
lation in the heart is a diagnostically useful finding. However, the usefulness of 18F-
FDG PET has been increasingly recognized; the Japanese health insurance system
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approved it for detection of inflammation sites in cardiac sarcoidosis on April 2012.
Recently, the Heart Rhythm Society of the USA also proposed the diagnosis and
management of cardiac sarcoidosis with 18F-FDG PET and MRI recommended for
the evaluation of cardiac sarcoidosis, if there is a cardiac history and abnormality in
the electrocardiogram or echocardiography in sarcoidosis patients [8].
16.3 Cardiac Metabolism
For the cardiac metabolism, under long fasting conditions, glucose production and
glucose oxidation would decrease. As a result, free fatty acid (FFA) is mobilized
from adipose tissue, and the increase in available FFA becomes an alternative
source of energy in the myocardium. The 18F-FDG is a glucose analog used clinic-
ally in PET to indicate glucose utilization (Fig. 16.1), and physiological myocardial
uptake has been reported. The levels of the cardiac uptake vary regardless of
blood glucose levels [9].
16.4 18F-FDG Uptake Patterns in Evaluations of Cardiac
Sarcoidosis
To evaluate cardiac sarcoidosis, uptake patterns of 18F-FDG were divided into four
kinds as suggested in Fig. 16.2 [7]. Without myocardial 18F-FDG uptake is consi-
dered to be negative in active cardiac lesions. A distinct diffuse 18F-FDG uptake in
the entire left ventricular wall without localized high 18F-FDG uptake generally is
Fig. 16.1 Chemical structural formula of D-glucose and 18F-FDG.
The chemical structural formulas of the glucose and 18F-fluorodeoxyglucose (18F-FDG) are shown
in panels A and B, respectively. 18F-FDG is a glucose analog widely used in PET studies of
glucose metabolism. 18F-FDG is taken up by plasma-membrane transporters and phosphorylated
by the intracellular enzymes in the same manner as glucose. The metabolism of 18F-FDG stops
after 6-phosphorylation which is different from glucose and provides an advantage in metabolism
studies
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thought to represent a physiological uptake, not indicating an abnormality. Focal
and focal on diffuse 18F-FDG uptakes in the left ventricular wall are considered to
be positive indicators of cardiac sarcoidosis.
16.5 Preparation for the 18F-FDG PET to Evaluate
Cardiac Lesions
The physiological myocardial 18F-FDG uptake may mislead when attempting to
establish cardiac sarcoidosis. Proper preparation such as extended fasting with a
low-carbohydrate diet before the scan is needed to suppress the physiological
cardiac uptake [10]. We have confirmed the usefulness of the effect of 18 h of
fasting with a low-carbohydrate diet compared to a minimum 6-h fasting prepar-
ation [9]. Patients with at least 6 h of fasting showed a higher diffuse left ventricular
(LV) 18F-FDG uptake than patients with longer fasting and low-carbohydrate diets.
Patients who fasted for longer and observed a low-carbohydrate diet showed
higher FFA levels than a shorter fasting group. In the shorter fasting group, patients
with diffuse LV 18F-FDG uptake showed significantly lower FFA levels than
patients without a diffuse LV uptake. This shows that the FFA level is an important
marker to suppress physiological 18F-FDG uptake. The protocol to obtain better
18F-FDG PET images in cardiac sarcoidosis patients is shown in Fig. 16.3.
Fig. 16.2 18F-FDG uptake patterns to evaluate cardiac sarcoidosis.
Uptake patterns were divided into four groups. No 18F-fluorodeoxyglucose (18F-FDG) uptake is
considered to be a negative sign for any active cardiac lesion (a). A diffuse 18F-FDG uptake in the
entire left ventricular wall without any localized high 18F-FDG uptake is generally thought to be a
physiological uptake (b). With slight accumulation in (b), it was not possible to determine if this
was caused by cardiac sarcoidosis. Focal uptake (c) and focal on diffuse uptakes (d) of 18F-FDG in
the left ventricular wall are considered to be positive signs for cardiac sarcoidosis
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16.6 Location of the 18F-FDG Uptake
Cardiac sarcoidosis provoked the conduction disturbance such as atrioventricular
block. There is a relationship between electrocardiogram abnormalities and myo-
cardial 18F-FDG uptake. In particular, the focal 18F-FDG uptake in the inter-
ventricular septum in cardiac sarcoidosis is associated with atrioventricular
blockage. Therefore, to identify the location of the 18F-FDG uptake is an important
issue of potentially great benefit in treatment planning [11].
The 18F-FDG uptake due to inflammation in the LV wall is sometimes difficult
to distinguish from the physiological uptake. On the other hand, the physiological
uptake in the right ventricle (RV) is less common and less intense. Therefore,
although less frequent of the sarcoidosis involvement, the 18F-FDG uptake in the
RV due to cardiac sarcoidosis may be useful in diagnosing in sarcoidosis [12].
16.7 Relationship Between 18F-FDG Accumulation
and Activity of Sarcoidosis
The significant 18F-FDG accumulation in cardiac sarcoidosis is caused by active
inflammatory changes involving activated inflammatory cells like neutrophils,
macrophages, and lymphocytes [13], and the 18F-FDG uptake may reflect an active
inflammation condition. This makes 18F-FDG PET useful both for the detection of
cardiac sarcoidosis as well as for monitoring the treatment response and early
recurrence [14].
The maximum standardized uptake value (SUVmax) has been used for semi-
quantitative measurements to assess the intensity of 18F-FDG uptake. Recently, the
availability of volume-based analysis, such as metabolic volume and total lesion
glycolysis, has been widely used to evaluate the extent and activity of the 18F-FDG
uptake in malignant tumors [15]. Ahmadian et al. applied volume-based analysis to
cardiac sarcoidosis and reported that the metabolic activity estimated by 18F-FDG
PET was a reliable independent predictor of cardiac events in cardiac sarcoidosis
patients [16]. A volume-based quantification of 18F-FDG uptake could be of value
Fig. 16.3 The protocol for the 18F-FDG PET scanning for cardiac sarcoidosis.
Patients were instructed to observe a low-carbohydrate or high-fat diet on the day prior to the
scanning, with additional fasting for more than 18 h. The PET images were acquired 60 min after
injection of the 18F-FDG
16 Usefulness of 18F-FDG PET in Diagnosing Cardiac Sarcoidosis 213
Fig. 16.4 Representative case.
This is a case of a cardiac sarcoidosis patient with uveitis and respiratory discomfort. She had a
right bundle branch block and right axis deviation on the electrocardiograph and thinning of the
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in a number of fields of cardiac and inflammation diseases like it is for malignant
tumors (Fig. 16.4).
16.8 Conclusions
Observations from 18F-FDG PET images are a useful diagnostic tool to detect
active inflammatory lesions associated with cardiac sarcoidosis. For a precise evalu-
ation of the extent and severity of cardiac involvement, long fasting and dietary
modifications, such as observing a low-carbohydrate or a high-fat diet, are recom-
mended approaches to reduce physiological myocardial 18F-FDG uptake. The FFA
level before the PET data acquisition could be a predictor for success in the suppres-
sion of physiological 18F-FDG accumulation. Such 18F-FDG PET images also
enable therapy monitoring or risk stratification based on the quantitative accumu-
lation determination. The quantification of the volume and intensity of 18F-FDG
uptake may also help predict the clinical outcomes and evaluate the efficiency of
steroid treatment.
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Fig. 16.4 (continued) septal wall with severe hypokinesis on the echocardiograph. There was a
clearly abnormal 18F-FDG uptake in the LV wall as well as in the lymph nodes which indicated
active inflammatory changes associated with sarcoidosis (a). The estimated maximum standard-
ized uptake value (SUVmax) was 10.6, and the volume of the uptake was 76.1 ml (the threshold
was obtained from the liver uptake) at the cardiac lesion. The 18F-FDG PET [revealed the
dramatic] showed a nearly total disappearance of the abnormal cardiac uptake after 4 weeks of
therapy with prednisolone (b). However, the 18F-FDG PET during the tapering of the prednisolone
showed renewed 18F-FDG uptake. Here, the estimated maximum standardized uptake value
(SUVmax) was 6.2, and the volume of the uptake was 7.83 ml (the threshold was obtained from
the liver uptake). This case indicates that 18F-FDG was useful to evaluate the sarcoidosis activity
and indicated the improvement during the therapy as well as the recurrence of the active
sarcoidosis
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